Interleukin-2 enhances angiogenesis and preserves cardiac function following myocardial infarction

Cytokine

Volumn 56, Issue 3, 2011, Pages 732-738

  Bouchentouf, M ^a   Williams, P ^a   Forner, K A ^a   Cuerquis, J ^a   Michaud, V ^a   Paradis, P ^a   Schiffrin, E L ^a,b   Galipeau, J ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Inflammation; Interleukin 2; Myocardial infarction; NK cells

Indexed keywords

COLLAGEN; RECOMBINANT INTERLEUKIN 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SCAR FORMATION; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION;

ANIMALS; CELL COUNT; CELL PROLIFERATION; COLLAGEN; ENDOTHELIAL CELLS; FLOW CYTOMETRY; HEART; HEART FUNCTION TESTS; HEART VENTRICLES; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, SCID; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; ORGAN SIZE;

MUS;

EID: 81455131474     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.09.023     Document Type: Article

References (49)

1. Blankesteijn W.M., Creemers E., Lutgens E., Cleutjens J.P., Daemen M.J., Smits J.F. Dynamics of cardiac wound healing following myocardial infarction: observations in genetically altered mice. Acta Physiol Scand 2001, 173:75-82.
2. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation 2003, 108:1395-1403.
3. Ren G., Dewald O., Frangogiannis N.G. Inflammatory mechanisms in myocardial infarction. Curr Drug Targets Inflamm Allergy 2003, 2:242-256.
4. Entman M.L., Youker K.A., Frangogiannis N., Lakshminarayanan V., Nossuli T., Evans A., et al. Is inflammation good for the ischemic heart-perspectives beyond the ordinary. Z Kardiol 2000, 89(Suppl 9):IX/82-IX/87.
5. Lindsey M., Wedin K., Brown M.D., Keller C., Evans A.J., Smolen J., et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001, 103:2181-2187.
6. Frangogiannis N.G., Mendoza L.H., Lindsey M.L., Ballantyne C.M., Michael L.H., Smith C.W., et al. IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J Immunol 2000, 165:2798-2808.
7. Goodchild T.T., Robinson K.A., Pang W., Tondato F., Cui J., Arrington J., et al. Bone marrow-derived B cells preserve ventricular function after acute myocardial infarction. JACC Cardiovasc Interv 2009, 2:1005-1016.
8. Bouchentouf M., Forner K.A., Cuerquis J., Michaud V., Zheng J., Paradis P., et al. Induction of cardiac angiogenesis requires killer cell lectin-like receptor 1 and alpha4beta7 integrin expression by NK cells. J Immunol 2010, 185:7014-7025.
9. Varda-Bloom N., Leor J., Ohad D.G., Hasin Y., Amar M., Fixler R., et al. Cytotoxic T lymphocytes are activated following myocardial infarction and can recognize and kill healthy myocytes in vitro. J Mol Cell Cardiol 2000, 32:2141-2149.
10. Ayach B.B., Yoshimitsu M., Dawood F., Sun M., Arab S., Chen M., et al. Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. Proc Natl Acad Sci USA 2006, 103:2304-2309.
11. Frangogiannis N.G. The role of the chemokines in myocardial ischemia and reperfusion. Curr Vasc Pharmacol 2004, 2:163-174.
12. Koch M., Savvatis K., Scheeler M., Dhayat S., Bonaventura K., Pohl T., et al. Immunosuppression with an interleukin-2 fusion protein leads to improved LV function in experimental ischemic cardiomyopathy. Int Immunopharmacol 2010, 10:207-212.
13. Hochman J.S., Choo H. Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation 1987, 75:299-306.
14. Cooper W.A., Corvera J.S., Thourani V.H., Puskas J.D., Craver J.M., Lattouf O.M., et al. Perfusion-assisted direct coronary artery bypass provides early reperfusion of ischemic myocardium and facilitates complete revascularization. Ann Thorac Surg 2003, 75:1132-1139.
15. Bouchentouf M., Paradis P., Forner K., Cuerquis J., Boivin M., Jiamin Z., et al. Monocyte derivatives promote angiogenesis and myocyte survival in a model of myocardial infarction. Cell Transplant 2009.
16. Eckle T., Grenz A., Kohler D., Redel A., Falk M., Rolauffs B., et al. Systematic evaluation of a novel model for cardiac ischemic preconditioning in mice. Am J Physiol Heart Circ Physiol 2006, 291:H2533-H2540.
17. Metzler B., Hammerer-Lercher A., Jehle J., Dietrich H., Pachinger O., Xu Q., et al. Plasma cardiac troponin T closely correlates with infarct size in a mouse model of acute myocardial infarction. Clin Chim Acta 2002, 325:87-90.
18. Mosmann T.R., Yokota T., Kastelein R., Zurawski S.M., Arai N., Takebe Y. Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4). J Immunol 1987, 138:1813-1816.
19. Caporale A., Brescia A., Galati G., Castelli M., Saputo S., Terrenato I., et al. Locoregional IL-2 therapy in the treatment of colon cancer. Cell-induced lesions of a murine model. Anticancer Res 2007, 27:985-989.
20. Schirrmacher V., Muerkoster S., Umansky V. Antagonistic effects of systemic interleukin 2 on immune Tcell-mediated graft-versus-leukemia reactivity. Clin Cancer Res 1998, 4:2635-2645.
21. Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res 2002, 53:31-47.
22. Aries A., Paradis P., Lefebvre C., Schwartz R.J., Nemer M. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci USA 2004, 101:6975-6980.
23. Iglarz M., Touyz R.M., Viel E.C., Paradis P., Amiri F., Diep Q.N., et al. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 2003, 42:737-743.
24. Bouchentouf M., Forner K., Cuerquis J., Boulassel M.R., Routy J.P., Waller E.K., et al. A novel and simplified method of culture of human blood derived early endothelial progenitor cells for the treatment of ischemic vascular disease. Cell Transplant 2011.
25. Bouchentouf M., Paradis P., Forner K.A., Cuerquis J., Boivin M.N., Zheng J., et al. Monocyte derivatives promote angiogenesis and myocyte survival in a model of myocardial infarction. Cell Transplant 2010, 19:369-386.
26. Gaebel R., Furlani D., Sorg H., Polchow B., Frank J., Bieback K., et al. Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration. PLoS One 2011, 6:e15652.
27. Fraccarollo D., Berger S., Galuppo P., Kneitz S., Hein L., Schutz G., et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 2011, 123:400-408.
28. Ma N., Stamm C., Kaminski A., Li W., Kleine H.D., Muller-Hilke B., et al. Human cord blood cells induce angiogenesis following myocardial infarction in NOD/scid-mice. Cardiovasc Res 2005, 66:45-54.
29. Haunstetter A., Izumo S. Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res 1998, 82:1111-1129.
30. Jordan J.E., Zhao Z.Q., Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 1999, 43:860-878.
31. Murphy G., Gavrilovic J. Proteolysis and cell migration: creating a path?. Curr Opin Cell Biol 1999, 11:614-621.
32. Ulrich M.M., Janssen A.M., Daemen M.J., Rappaport L., Samuel J.L., Contard F., et al. Increased expression of fibronectin isoforms after myocardial infarction in rats. J Mol Cell Cardiol 1997, 29:2533-2543.
33. Battegay E.J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995, 73:333-346.
34. Yang F., Liu Y.H., Yang X.P., Xu J., Kapke A., Carretero O.A. Myocardial infarction and cardiac remodelling in mice. Exp Physiol 2002, 87:547-555.
35. Maisel A., Cesario D., Baird S., Rehman J., Haghighi P., Carter S. Experimental autoimmune myocarditis produced by adoptive transfer of splenocytes after myocardial infarction. Circ Res 1998, 82:458-463.
36. Moraru M., Roth A., Keren G., George J. Cellular autoimmunity to cardiac myosin in patients with a recent myocardial infarction. Int J Cardiol 2006, 107:61-66.
37. Lu L., Chen S.S., Zhang J.Q., Ramires F.J., Sun Y. Activation of nuclear factor-kappaB and its proinflammatory mediator cascade in the infarcted rat heart. Biochem Biophys Res Commun 2004, 321:879-885.
38. Martinez Rosas M. Cardiac remodeling and inflammation. Arch Cardiol Mex 2006, 76(Suppl 4):S58-S66.
39. Mehta J.L., Li D.Y. Inflammation in ischemic heart disease: response to tissue injury or a pathogenetic villain?. Cardiovasc Res 1999, 43:291-299.
40. Roberts R., DeMello V., Sobel B.E. Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation 1976, 53:I204-I206.
41. Mann D.L., McMurray J.J., Packer M., Swedberg K., Borer J.S., Colucci W.S., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation 2004, 109:1594-1602.
42. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy against congestive heart failure (ATTACH) trial. Circulation 2003, 107:3133-3140.
43. Hasegawa H., Takano H., Iwanaga K., Ohtsuka M., Qin Y., Niitsuma Y., et al. Cardioprotective effects of granulocyte colony-stimulating factor in swine with chronic myocardial ischemia. J Am Coll Cardiol 2006, 47:842-849.
44. Ohtsuka M., Takano H., Zou Y., Toko H., Akazawa H., Qin Y., et al. Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. FASEB J 2004, 18:851-853.
45. Krishnamurthy P., Rajasingh J., Lambers E., Qin G., Losordo D.W., Kishore R. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res 2009, 104:e9-e18.
46. Burchfield J.S., Iwasaki M., Koyanagi M., Urbich C., Rosenthal N., Zeiher A.M., et al. Interleukin-10 from transplanted bone marrow mononuclear cells contributes to cardiac protection after myocardial infarction. Circ Res 2008, 103:203-211.
47. Takeshita S., Isshiki T., Ochiai M., Ishikawa T., Nishiyama Y., Fusano T., et al. Systemic inflammatory responses in acute coronary syndrome: increased activity observed in polymorphonuclear leukocytes but not T lymphocytes. Atherosclerosis 1997, 135:187-192.
48. Atkins M.B., Sparano J., Fisher R.I., Weiss G.R., Margolin K.A., Fink K.I., et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993, 11:661-670.
49. Schwartzentruber D.J. High-dose interleukin-2 is an intensive treatment regardless of the venue of administration. Cancer J 2001, 7:103-104.